Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Bruno Roche; Artur Bauhofer; Miguel Ãngel Gomez Bravo; Georges Philippe Pageaux; Fabien Zoulim; Alejandra Otero; Martin Prieto; Carmen Baliellas; Didier Samuel

doi:10.12659/AOT.936162

10 May 2022 : Original article

Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Bruno Roche^1BCDE, Artur Bauhofer^2ACDEF*, Miguel Ãngel Gomez Bravo^3BCDE, Georges Philippe Pageaux^4ABCDE, Fabien Zoulim^5BDE, Alejandra Otero^6BC, Martin Prieto^78BC, Carmen Baliellas^9BC, Didier Samuel^1ACDE

DOI: 10.12659/AOT.936162

Ann Transplant 2022; 27:e936162

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Table 3 Post-transplant HBV recurrence and HCC recurrence.

	HBV recurrence		HCC recurrence
	Based on HBsAg and/or HBV DNA	Based on HBV DNA only	HCC recurrence
Patients, n (%)/95% CI^*	7 (3.6)/1.5–7.3%	1 (0.5)/0–2.8%	4 (4.8)/1.3–11.9%
Annual rate	2.01%	0.29%	2.88%
Time to event after LT [months], median (min, max)	18.5 (13.1, 34.6)	34.6	17.5 (12.5, 22.2)
^* Based on all 195 patients (HBV recurrence) or 83 patients with HCC as primary indication for LT (HCC recurrence). CI – confidence interval; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HCC – hepatocellular carcinoma; LT – liver transplantation.

Back to the Article

Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Your Privacy